Sinsin Pharmaceutical KRX:002800KOSDAQ
신신제약 · Korean news coverage and regulatory filings, organized.
Articles, 24h1
Articles, 7 days1
DART filings, 7 days0
Articles tracked3since Sep 11
In Q2 2026, Sinsin Pharmaceutical reported revenue of ₩34.0bn, up 14.9% year on year, and operating profit of ₩4.1bn. Sinsin Pharmaceutical (신신제약) appeared in 1 Korean news article and 0 DART filings over the past seven days. Coverage peaked on Oct 30 with 1 article.
Filing signals Profit +50% Revenue & profit growth Screener
Sinsin Pharmaceutical quarterly results consolidated, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩34.0bn | +14.9% | ₩4.1bn margin 12.0% | ₩3.6bn |
| Q1 2026 | ₩30.2bn | +19.2% | ₩3.2bn margin 10.5% | ₩2.9bn |
| Q4 2025 derived | ₩28.8bn | +13.8% | ₩3.3bn margin 11.6% | ₩3.5bn |
| Q3 2025 | ₩30.1bn | +11.7% | ₩4.0bn margin 13.1% | ₩3.4bn |
| Q2 2025 | ₩29.6bn | +0.5% | ₩2.2bn margin 7.5% | ₩1.4bn |
| Q1 2025 | ₩25.3bn | +2.4% | ₩1.3bn margin 5.0% | ₩994m |
| Q4 2024 derived | ₩25.3bn | +2.7% | ₩1.2bn margin 4.6% | ₩709m |
| Q3 2024 | ₩27.0bn | +1.8% | ₩1.9bn margin 6.9% | ₩1.0bn |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
Sinsin Pharmaceutical top stories 2 weeks, by number of outlets
- 1